Which critical medicines are in short supply in the European Union?
ADVERTISEMENT
The European Union is in short supply of 16 medicines that are considered 'critical' for people's health.
A drug can be put on the EU's shortages list because of production issues, a surge in demand, or a drugmaker deciding to pull it off the market – anything that limits the bloc's supply on either a temporary or permanent basis.
There are ongoing shortages of 34 medicines, according to the European Medicines Agency (EMA). Sixteen of those are on the EU's list of essential drugs that the European Commission aims to bolster through its new Critical Medicines Act.
Here are the critical medicines in short supply in the EU, according to the latest available information from the EMA and member states.
Cyanide poisoning antidote
Cyanokit is the only EU-approved medicine to treat cyanide poisoning. It contains the active ingredient hydroxocobalamin or vitamin B12a, which is on the EU's critical medicines list.
In December 2024, health authorities said Cyanokit manufacturing was being suspended after the drugmaker discovered that some batches may have been contaminated. However, because the risk of contamination is low and there is no alternative antidote, they are still in circulation, according to the EMA. The shortage is expected to be resolved by May 2025.
Amoxicillin
Amoxicillin is an antibiotic for bacterial infections. Shortages began in October 2022 after an uptick in respiratory illnesses led to higher demand for antibiotics.
Related Big pharma urges Commission to slow down on new critical medicines rules
Manufacturers also lacked enough staff to make the medicine, the EMA said. These issues have since eased in most countries, but some intermittent supply problems persist across Europe.
Some inhalers
People with asthma, chronic obstructive pulmonary disease (COPD), and other breathing issues take salbutamol, typically using an inhaler or a nebuliser.
Manufacturers are struggling to meet the growing demand for inhalers, leading to intermittent shortages of salbutamol across most of the EU. Alternatives are available, but the scarcity is expected to last until at least mid-2025.
A few types of insulin
Patients with type 1 or 2 diabetes take insulin to control their blood sugar. Manufacturing problems for certain types of insulin – Insuman Rapid, Basal and Comb 25 – in early 2023, caused delays across the supply chain.
The drugmaker also decided to stop producing these types of insulin, prompting the EMA to urge doctors to transition their patients to other brands.
Seven cancer drugs
The EU does not have enough of seven drugs used to treat various types of cancers, including hycamtin, methotrexate, fludarabine, fluorouracil, cisplatin, fasturtec, and paclitaxel.
The shortages are mainly due to manufacturing problems, though unexpected demand for methotrexate injections – which can also help treat inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease – has exacerbated their scarcity in some European countries.
Shortages are beginning to be resolved for several of these medications, and in the meantime, alternative options are available for some of them.
ADVERTISEMENT
Vaccine for mosquito-borne virus
Ixiaro is a vaccine for Japanese encephalitis, which is related to the dengue, yellow fever, and West Nile viruses and causes brain inflammation. Increased demand and manufacturing problems caused a shortage of the vaccine, though supply levels have since improved.
The EMA expected the shortage, which has affected Ireland, Italy, Poland, Portugal, and Spain, to be resolved by late January, but Irish authorities now say it should be back in stock there by the end of April 2025.
Blood disease medicine
Peginterferon alfa-2a, sold as Pegasys, is used to treat chronic hepatitis B and C as well as other blood diseases.
Unexpectedly high demand for the medicine has led to shortages that the EMA said should be resolved later in 2025.
ADVERTISEMENT
Schizophrenia treatment
Zypadhera, also known as olanzapine, helps treat schizophrenia.
Patients who have taken the drug by mouth can then start taking it via injection – but the needles are in short supply due to manufacturing issues, leading to intermittent shortages of Zypadhera in some European countries. Limited quantities are now available in places like Belgium.
Heart attack prevention drug
Integrilin can help prevent heart attacks for adults with severe chest pain and those who have already had a certain type of heart attack.
Supply issues with the active ingredient, eptifibatide, prompted drugmaker GlaxoSmithKline to stop manufacturing the medicine and pull it off the EU market. However, alternatives are available.
ADVERTISEMENT
Eye problems medicine
Verteporfin, sold as Visudyne, is a treatment for people with certain eye problems, for example a type of age-related macular degeneration.
Manufacturing has been limited since May 2020, leaving the medicine in short supply, though other treatments are available. Limited quantities are now available in places like Austria, with a restock there expected by the end of 2025.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Local France
7 hours ago
- Local France
France adopts law upholding ban on controversial insecticide
The legislation has been at the heart of a major debate in France and sparked a student-initiated petition that was wildly successful. READ MORE: What is France's Loi Duplomb and why are people protesting about it? Critics of the bill, adopted in July in a fractured lower house of parliament, say it was rushed through without proper debate. The law was published in the government's official journal on Tuesday after the Constitutional Council, the country's highest court, struck down the contested provision about the reintroduction of acetamiprid. The court said that the insecticides known as neonicotinoids posed "risks to human health" and were unconstitutional as they undermined the right to live in a balanced and healthy environment as guaranteed in the country's environmental charter. Banned in France since 2018, acetamiprid is legal in the European Union and proponents say French farmers need it to help them compete with their European counterparts. Advertisement The main farmers' union has railed against the court ruling. Supporters of the petition said their frustration with the legislation went beyond environmental concerns. Commentators have said it may be a sign of exasperation with deadlock in a hung parliament and a desire to have a greater say in political matters. After the ruling, Macron had said he intended to quickly enact the law and rejected further parliamentary debate. The controversial legislation has been dubbed the Duplomb law, after its author, Laurent Duplomb, a senator for the right-wing Les Republicains party. French Health Minister Yannick Neuder has called for a European reassessment of the impact of acetamiprid on human health.
Euronews
4 days ago
- Euronews
EU agencies seek to combat viral hepatitis in European prisons
EU agencies for disease prevention and drugs have together launched a toolkit to support efforts to eliminate viral hepatitis in Europe's prisons. The initiative by the European Centre for Disease Prevention and Control and the European Drugs Agency, supports the World Health Organisation's target to eliminate viral hepatitis as a public health threat by 2030. Published ahead of Prisoners' Justice Day (10 August), the guide aims to support hepatitis B and C prevention and care in prisons across Europe. It is primarily intended for professionals working in prison healthcare services and provides information on how to set up interventions to prevent and control viral hepatitis in these settings. The number of prisoners in the EU was around 499,000 in 2023, equivalent to 111 prisoners per 100,000 inhabitants, according to the European Commission, representing a 3.2% increase compared with 2022. In the EU, hepatitis B and C prevalence is highest among certain populations, including migrants, people who inject drugs, men who have sex with men, sex workers, and people in prison. This makes prisons a high-risk environment for hepatitis B and C transmission, as prison populations and people who inject drugs often overlap, according to the agencies. 'Incarceration and drug use are therefore intertwined and lead to increased risks of infection with communicable diseases,' the toolkit notes. The scarcity of access to clean injecting equipment in most prison settings further increases the risk, not only for drug use but also for tattoos and body piercings. Hepatitis B and hepatitis C are major causes of cirrhosis, liver cancer, liver transplantation, and liver related deaths. The WHO estimates that 10.6 million people in Europe are living with chronic hepatitis B, and 8.6 million with chronic hepatitis C, the majority of whom remain undiagnosed. Both agencies highlight the unique challenges of addressing this issue in the prison context — including insufficient resources, lack of training, and underdeveloped public health surveillance and monitoring systems — all of which can hinder the implementation of recommendations. They also stress the need to tackle these infections not only to improve individual health outcomes for prisoners but also to reduce transmission within prisons and in the wider community upon release.
France 24
5 days ago
- France 24
Humanitarian situation in Gaza still very severe, EU official says
The humanitarian situation in Gaza continues to be very severe, an EU official told Reuters after the EU's foreign policy and humanitarian arms updated member countries late on Wednesday on the status of an agreement reached with Israel last month on boosting humanitarian access to Gaza. The official said on Thursday that there were some positive developments regarding fuel delivery, the reopening of some routes, and an upward trend in the number of daily trucks entering the enclave and the repair of some vital infrastructure. However, the official added that "significant obstructive factors continue to undermine humanitarian operations and aid delivery to Gaza, notably the lack of a safe operating environment to allow the distribution of aid at scale". 02:24 Israel enforced a complete blockade on food and other supplies for two-and-a-half months beginning in March. Though the flow of aid resumed in May under mounting international outrage, the amount that Israel is letting into the besieged territory is a fraction of what aid organisations say is needed. The UN has warned that a famine is unfolding in the besieged territory, which is home to more than two million Palestinians. At least 38 Palestinians were killed on Wednesday in the Gaza Strip while seeking aid from United Nations convoys and sites run by Israeli-backed American contractor Global Humanitarian Foundation, according to local health officials. Another 25 people, including several women and children, were killed in Israeli air strikes, according to local hospitals in Gaza. The military maintains that it only targets Hamas militants.
